Gossamer Bio (GOSS) Aktievy
Gossamer Bio, Inc. är ett biofarmaceutiskt företag i klinisk fas som fokuserar på att utveckla och kommersialisera seralutinib för behandling av pulmonell hypertension och pulmonell arteriell hypertension i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 5/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 1/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
+ 1 större risk
GOSS Community Fair Values
Create NarrativeSee what 34 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Gossamer Bio, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$0.17 |
| 52 veckors högsta | US$3.87 |
| 52 veckors lägsta | US$0.14 |
| Beta | 2.04 |
| 1 månads förändring | -1.03% |
| 3 månaders förändring | -47.47% |
| 1 års förändring | -86.14% |
| 3 års förändring | -88.06% |
| 5 års förändring | -97.81% |
| Förändring sedan börsintroduktionen | -99.03% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 01
GOSS: Balance Sheet Cleanup And Listing Compliance Will Drive Potential Rerating
Analysts have cut Gossamer Bio's fair value estimate from about $4.46 to $3.86, reflecting lower published price targets after dilution from the convertible note exchange and concern around funding and going concern risks. Analyst Commentary Recent Street research on Gossamer Bio highlights a split view, with some focusing on balance sheet clean up and others emphasizing dilution and funding risks.Uppdatering av berättelse • Jun 17
GOSS: Upcoming Liquidity And Listing Decisions Will Drive Potential Rerating
The analyst price target for Gossamer Bio has been cut to $0.28, with analysts citing the firm's going concern warning, uncertainty around future funding, and equity dilution from the 2027 notes exchange as key reasons for the reduced visibility on the stock. Analyst Commentary Recent research on Gossamer Bio highlights a cautious stance, with a focus on liquidity, capital structure, and the impact of recent financing moves on valuation and execution risk.Uppdatering av berättelse • Jun 03
GOSS: Upcoming Regulatory Updates On Lead Program Will Drive Potential Rerating
Analysts have cut Gossamer Bio's $5.00 fair value estimate to $4.46 and now apply a higher 12.46% discount rate and a richer 104.9x future P/E, reflecting concerns around going concern risks, equity dilution from the debt exchange, and regulatory uncertainty around seralutinib, even as some still highlight its potential in pulmonary arterial hypertension. Analyst Commentary Street research around Gossamer Bio is split, with some analysts emphasizing upside tied to seralutinib's potential in pulmonary arterial hypertension and others focusing on funding risks, dilution, and regulatory uncertainty.Recent updates
Uppdatering av berättelse • Jul 01
GOSS: Balance Sheet Cleanup And Listing Compliance Will Drive Potential Rerating
Analysts have cut Gossamer Bio's fair value estimate from about $4.46 to $3.86, reflecting lower published price targets after dilution from the convertible note exchange and concern around funding and going concern risks. Analyst Commentary Recent Street research on Gossamer Bio highlights a split view, with some focusing on balance sheet clean up and others emphasizing dilution and funding risks.Uppdatering av berättelse • Jun 17
GOSS: Upcoming Liquidity And Listing Decisions Will Drive Potential Rerating
The analyst price target for Gossamer Bio has been cut to $0.28, with analysts citing the firm's going concern warning, uncertainty around future funding, and equity dilution from the 2027 notes exchange as key reasons for the reduced visibility on the stock. Analyst Commentary Recent research on Gossamer Bio highlights a cautious stance, with a focus on liquidity, capital structure, and the impact of recent financing moves on valuation and execution risk.Uppdatering av berättelse • Jun 03
GOSS: Upcoming Regulatory Updates On Lead Program Will Drive Potential Rerating
Analysts have cut Gossamer Bio's $5.00 fair value estimate to $4.46 and now apply a higher 12.46% discount rate and a richer 104.9x future P/E, reflecting concerns around going concern risks, equity dilution from the debt exchange, and regulatory uncertainty around seralutinib, even as some still highlight its potential in pulmonary arterial hypertension. Analyst Commentary Street research around Gossamer Bio is split, with some analysts emphasizing upside tied to seralutinib's potential in pulmonary arterial hypertension and others focusing on funding risks, dilution, and regulatory uncertainty.Uppdatering av berättelse • May 09
GOSS: Upcoming FDA Talks On Phase 3 Data Will Drive Potential Rerating
Narrative Update Gossamer Bio's analyst price targets have been reset sharply lower, with cuts from as high as $12 to as low as $0.30. Analysts are factoring in weaker than expected Phase 3 PROSERA data, a clouded regulatory path for seralutinib in pulmonary arterial hypertension, and added balance sheet and funding uncertainties.Uppdatering av berättelse • Apr 22
GOSS: Upcoming FDA Meeting Will Determine Potential Rerating After Phase 3 Setback
Analysts have lowered their average price targets on Gossamer Bio into the low single-digit dollar range, reflecting reduced modeled revenue growth, a higher discount rate, and increased regulatory uncertainty around seralutinib following the recent Phase 3 PROSERA miss and multiple rating downgrades. Analyst Commentary Recent Street research around Gossamer Bio clusters around two themes: how to weigh the mixed seralutinib data against the regulatory risk, and how to factor balance sheet constraints into valuation.
Uppdatering av berättelse • Apr 07
GOSS: Regulatory Path And Funding Outlook Will Shape Future Repricing Potential
Narrative Update: Gossamer Bio The average analyst price target for Gossamer Bio has moved sharply lower into the low single digits, with firms citing reduced probabilities of success for seralutinib in pulmonary arterial hypertension, a mixed Phase 3 PROSERA outcome that missed its primary endpoint, and added regulatory and funding uncertainty as key drivers behind the reset. Analyst Commentary Recent Street research around Gossamer Bio has turned more cautious, with several bearish analysts reacting to the Phase 3 PROSERA miss, regulatory uncertainty for seralutinib in pulmonary arterial hypertension, and funding needs.
Uppdatering av berättelse • Mar 24
GOSS: Regulatory Meetings On Phase 3 Miss Will Drive Future Rerating Potential
Narrative Update The analyst price target for Gossamer Bio has been reduced, with fair value moving from $15.00 to about $13.43 as analysts factor in a lower assumed probability of success for seralutinib in pulmonary arterial hypertension, heightened regulatory uncertainty after the Phase 3 PROSERA miss, and balance sheet concerns. These factors are partially offset by ongoing expectations for higher revenue growth, stronger profit margins, and a lower future P/E multiple.Uppdatering av berättelse • Mar 08
GOSS: Upcoming FDA Meeting And 2026 Data Readouts Will Drive Rerating Potential
Analysts have sharply reduced their average price targets on Gossamer Bio, cutting them from a prior fair value indication of about $9.50 to roughly $3.69. This change reflects reduced confidence in seralutinib's regulatory path and a reevaluation of risk after the PROSERA Phase 3 miss.Uppdatering av berättelse • Feb 21
GOSS: Index Additions And Barclays Bullish Coverage Will Support Future Repricing
Analysts have raised their price target on Gossamer Bio to $6.00, citing new bullish coverage that outlines the company’s updated assumptions for risk, growth, margins and future P/E, while maintaining their fair value estimate at $6.00. Analyst Commentary While the updated price target of US$6.00 reflects a constructive view on Gossamer Bio, some research commentary also highlights areas where expectations could be tested.Uppdatering av berättelse • Feb 07
GOSS: Index Additions And Bullish Research Coverage Will Support Future Repricing
Analysts have adjusted their price target for Gossamer Bio to US$6.00, with the updated view supported by slightly revised assumptions on discount rate, revenue growth, profit margin and future P/E following fresh bullish Street research coverage. Analyst Commentary While the updated US$6.00 price target reflects constructive views in recent research, not all commentators are aligned with the bullish tone.Uppdatering av berättelse • Jan 23
GOSS: Index Additions And February 2026 Data Will Drive Rerating Potential
Analysts have maintained their fair value estimate for Gossamer Bio at US$9.50 per share. They explained that only modest adjustments to assumptions such as the discount rate and future P/E were required, and these did not affect their overall price target view.Analysartikel • Jan 22
Gossamer Bio, Inc.'s (NASDAQ:GOSS) Popularity With Investors Under Threat As Stock Sinks 27%
The Gossamer Bio, Inc. ( NASDAQ:GOSS ) share price has softened a substantial 27% over the previous 30 days, handing...Uppdatering av berättelse • Jan 09
GOSS: Index Additions And Updated Assumptions Will Support Bullish Repricing
Analysts have revised their price target on Gossamer Bio to US$6.00, with the unchanged fair value level tied to updated assumptions that include adjusted discount rates, a higher modeled revenue growth rate of 59.16% and a lower future P/E of about 63.33x. These factors together shape their latest view of the share price outlook.Seeking Alpha • Dec 19
Gossamer Bio: High-Risk Binary Approaches
Summary Gossamer Bio is approaching a binary catalyst with the February 2026 PROSERA phase 3 readout for seralutinib in pulmonary arterial hypertension. PROSERA differs from the phase 2 TORREY study, by focusing on 6MWD as the primary endpoint, enrolling higher-risk patients and more patients outside North America. GOSS is also running a trial of seralutinib in those with pulmonary hypertension associated with interstitial lung disease. That trial only got underway in Q4 '25, however. Read the full article on Seeking AlphaUppdatering av berättelse • Dec 14
GOSS: Upcoming Respiratory Congress Data Will Likely Drive Stronger Market Reassessment
Analysts have sharply raised their price target on Gossamer Bio, with fair value estimates climbing from approximately 1.25 to 6.00 per share. They cite expectations for significantly faster revenue growth and a higher future earnings multiple, despite a modest uptick in discount rates and slightly lower projected profit margins.Uppdatering av berättelse • Nov 28
GOSS: Improving Market Conviction Will Drive Momentum Into February 2026 Data Release
Analysts have maintained their price target for Gossamer Bio at $9.50 per share, citing increasingly positive sentiment and renewed conviction about seralutinib’s outlook as key clinical milestones approach. Analyst Commentary As key clinical milestones for seralutinib approach, analysts have weighed in with both optimistic and cautious perspectives regarding Gossamer Bio’s future prospects and current valuation.Analysartikel • Nov 25
Gossamer Bio, Inc.'s (NASDAQ:GOSS) 28% Share Price Surge Not Quite Adding Up
Gossamer Bio, Inc. ( NASDAQ:GOSS ) shareholders have had their patience rewarded with a 28% share price jump in the...Uppdatering av berättelse • Nov 14
GOSS: Improving Sentiment Will Drive Momentum Ahead of February 2026 Data Readout
Analysts have raised their price target for Gossamer Bio from $8.86 to $9.50. They cite increased conviction in the company's upcoming clinical data and improving market sentiment around its lead drug candidate.Analysartikel • Oct 11
Gossamer Bio, Inc. (NASDAQ:GOSS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Gossamer Bio, Inc. ( NASDAQ:GOSS ) shares have retraced a considerable 27% in the last month, reversing a fair amount...Uppdatering av berättelse • Sep 11
Phase III Trials And Global Collaborations Will Expand Treatment Horizons
Analysts have raised their price target for Gossamer Bio from $7.75 to $8.86, citing optimism for seralutinib's novel mechanism and market potential in pulmonary hypertension as key drivers. Analyst Commentary Positive outlook on Gossamer Bio's strategy in targeting pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.Analysartikel • Aug 22
Revenues Not Telling The Story For Gossamer Bio, Inc. (NASDAQ:GOSS) After Shares Rise 26%
Despite an already strong run, Gossamer Bio, Inc. ( NASDAQ:GOSS ) shares have been powering on, with a gain of 26% in...Ny berättelse • May 18
Phase III Trials And Global Collaborations Will Expand Treatment Horizons
Successful Phase III study enrollment and collaboration enhance market reach, promising revenue growth through potential positive efficacy results and expanded indications.Seeking Alpha • Feb 14
Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Summary Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far produced encouraging Phase 2 data and has an ongoing Phase 3 PROSERA trial for PAH. The main event comes with its topline results in Q4 2025. GOSS’s pipeline includes a PH-ILD program slated to start Phase 3 in mid-2025. This program addresses a larger, high-mortality TAM. Lastly, Gossamer Bio seems to have enough resources to fund both of these trials in 2025. So, I believe its cash runway is sufficient for now. In my view, GOSS is now basically a binary bet on the upcoming Phase 3 data by the end of the year, and for now, it looks reasonably priced relative to its upside potential. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
Summary Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025. Seralutinib's potential in PH-ILD and PAH, combined with its safety profile, positions it as a strong contender in the biopharmaceutical market. Read the full article on Seeking AlphaAnalysartikel • Aug 14
Brokers Are Upgrading Their Views On Gossamer Bio, Inc. (NASDAQ:GOSS) With These New Forecasts
Shareholders in Gossamer Bio, Inc. ( NASDAQ:GOSS ) may be thrilled to learn that the analysts have just delivered a...Seeking Alpha • Sep 27
Peaking Back In On Gossamer Bio
Summary Today, we look back in on a small biotech company called Gossamer Bio. The company's primary drug candidate is approaching a key trial milestone and analyst firms are currently sanguine on Gossamer's long-term prospects. An investment analysis follows in the paragraphs below. A humble man speaks not of his own humility" - Jeremy Aldana Today, we are shining the spotlight back on Gossamer Bio (GOSS) for the first time since our last article on this small biotech name back in October of last year. The stock trades almost exactly where it was during our last look at it, which given the carnage in the markets here in 2022, counts as a victory. The shares had some insider buying in July within a private placement. No one else on Seeking Alpha has touched on the company since we last revisited it. In addition, the stock has had a wild ride in recent months. Therefore, it seems to be a good time to incorporate developments in 2022 and update our take on Gossamer. An analysis follows below. Seeking Alpha Company Overview: Gossamer Bio is clinical-stage biopharmaceutical concern focused on the development or procurement of therapies in the areas of immunology, inflammation, and oncology. The company is based in San Diego and the stock currently trades at around $12.00 a share and sports an approximate market cap of $1.1 billion. Recent Developments: August Company Presentation The company has a couple of pipeline assets in development. The most important of which is a compound called seralutinib which is also known as GB002. This candidate is targeting Pulmonary Arterial Hypertension, commonly known as PAH. The condition is a function of abnormal cell growth within and around small blood vessels of the lung that move blood from the right side of the heart to the lungs. Despite products on the market to treat this condition, the five-year survival rate is just over 55%. August Company Presentation Seralutinib has Orphan Drug status both in Europe and U.S. for this indication. This candidate is an inhaled inhibitor of the following tyrosine kinases: platelet-derived growth factor receptors α and β (PDGFRs), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. It is designed to treat PAH as described in the slide above. August Company Presentation Currently, seralutinib is being evaluated in a Key Phase 2 trial called Torrey. This is a clinical study in patients with PAH whose disease has progressed despite standard-of-care therapy. The primary endpoint of this trial is the change in pulmonary vascular resistance from baseline at week 24. Topline results are scheduled to be out anywhere from the back half of November or first half of December of this year. August Company Presentation Last week, Wedbush reiterated their Buy rating on GOSS. The analyst there noted: This mid-stage trial has a high likelihood of success due to seralutinib's mechanism of action and positive results in both the preclinical and early-stage studies." She further stated that she 'believes that seralutinib has the potential to capture 42% of the market in the U.S. in 2030 with projected sales of $2.5B, assuming that the drug is launched in 2026.' August Company Presentation The company has a couple of other earlier staged assets in development. The only out of the clinic is GB5121. This is an oral, CNS-Penetrant BTK Inhibitor that is targeting Primary CNS Lymphoma (PCNSL) and other Rare CNS Malignancies. Currently, an open-label Phase 1b/2 study 'STAR' is underway to evaluate GB5121 for these indications. That study recently dosed its first patient. Management has stated that data from STAR will be presented at relevant medical conferences, as data become available. August Company Presentation Analyst Commentary & Balance Sheet: The company ended the second quarter with just over $220 million in cash and marketable securities on its balance sheet after posting a net loss for the quarter of $56.5 million. Two weeks after the quarter closed, management executed a private placement that raised an additional $120 million in proceeds. Four insiders including the CEO and CFO bought nearly $1.2 million in total of the private placement in mid-July. Up to that point, insiders had sold approximately $600,000 worth of shares in aggregate in 2022. Just over 20% of the outstanding float in GOSS is currently held short. The company has just over $200 million in long-term debt.Seeking Alpha • Jul 13
Gossamer Bio to raise $120M in a private equity placement
Gossamer Bio (NASDAQ:GOSS) to sell approximately 16.6M shares of its common stock at $7.21/share in a private placement. Gross proceeds are expected to be approximately $120M. The financing is expected to close on July 15. “We are very pleased this high-quality group of investors came together to support the seralutinib program at this important juncture,” said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer. “These additional funds will allow us to accelerate and expand our investment in seralutinib ahead of the Phase 2 TORREY Study topline results in the fourth quarter of this year.” In addition to supporting the seralutinib program, the company intends to use the net proceeds to fund research and development of its other product candidates and development programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash, cash equivalents and marketable securities, and access to its debt facility is expected to be sufficient to fund operating and capital expenditures into mid-2024.Analysartikel • Jun 25
Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Jan 19
Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Aktieägarnas avkastning
| GOSS | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 5.6% | 4.1% | 1.6% |
| 1Y | -86.1% | 41.1% | 18.6% |
Avkastning vs industri: GOSS presterade sämre än US Biotechs branschen som gav 41.1 % under det senaste året.
Avkastning vs Marknaden: GOSS presterade sämre än US marknaden som gav 18.6 % under det senaste året.
Prisvolatilitet
| GOSS volatility | |
|---|---|
| GOSS Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: GOSS s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: GOSS s veckovolatilitet ( 17% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2015 | 162 | Faheem Hasnain | www.gossamerbio.com |
Gossamer Bio, Inc. är ett biofarmaceutiskt företag i klinisk fas som fokuserar på att utveckla och kommersialisera seralutinib för behandling av pulmonell hypertension och pulmonell arteriell hypertension i USA. Företaget utvecklar GB002, en inhalerad, småmolekylär PDGFR-receptor (platelet-derived growth factor receptor), kolonistimulerande faktor 1-receptor och c-KIT-hämmare, som befinner sig i klinisk fas 3-studie för behandling av PAH. Bolaget har licensavtal med Pulmokine, Inc. för att utveckla och kommersialisera GB002 och relaterade backup-substanser.
Gossamer Bio, Inc. Sammanfattning av grunderna
| GOSS grundläggande statistik | |
|---|---|
| Börsvärde | US$84.67m |
| Vinst(TTM) | -US$180.40m |
| Intäkter(TTM) | US$55.54m |
1.5x
P/S-förhållande-0.5x
P/E-förhållandeÄr GOSS övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| GOSS resultaträkning (TTM) | |
|---|---|
| Intäkter | US$55.54m |
| Kostnad för intäkter | US$0 |
| Bruttovinst | US$55.54m |
| Övriga kostnader | US$235.93m |
| Intäkter | -US$180.40m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.37 |
| Bruttomarginal | 100.00% |
| Nettovinstmarginal | -324.82% |
| Skuld/egenkapitalförhållande | -123.1% |
Hur har GOSS utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/06 08:05 |
| Aktiekurs vid dagens slut | 2026/07/02 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Gossamer Bio, Inc. bevakas av 20 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Carter Gould | Barclays |
| Eliana Merle | Barclays |
| Zhilin Long | Berenberg |